HC Wainwright Has Positive Forecast for ONCY FY2025 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – HC Wainwright increased their FY2025 earnings estimates for Oncolytics Biotech in a report issued on Monday, November 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.25) per share for the year, up from their previous estimate of ($0.28). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.04) EPS.

ONCY has been the topic of a number of other reports. Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday. Lake Street Capital assumed coverage on Oncolytics Biotech in a report on Wednesday, August 13th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Oncolytics Biotech Stock Down 1.9%

Shares of ONCY stock opened at $1.03 on Wednesday. The company’s fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $0.96. Oncolytics Biotech has a 52 week low of $0.33 and a 52 week high of $1.51. The stock has a market cap of $103.37 million, a P/E ratio of -3.81 and a beta of 1.32.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02.

Institutional Investors Weigh In On Oncolytics Biotech

Large investors have recently added to or reduced their stakes in the stock. Scientech Research LLC bought a new stake in shares of Oncolytics Biotech in the 3rd quarter valued at approximately $25,000. Seeds Investor LLC raised its holdings in Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after buying an additional 33,826 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Oncolytics Biotech in the 3rd quarter worth about $535,000. 6.82% of the stock is owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.